Inc. · Aug 2025
Inc. profiles how Aakash and Manan Shah used Reddit and YouTube to grow Wyndly into a multimillion-dollar business, saying the company doubled sales in 2024 and surpassed $1M in its first year.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Wyndly is a doctor-founded telehealth allergy practice that offers at-home testing and personalized sublingual immunotherapy (SLIT) for environmental allergies, using a direct-to-patient, virtual care model.
Primary product
At-home allergy testing plus personalized sublingual immunotherapy treatment plans
Founded
2020
Headquarters
New York City, United States
Team size
11-50
Industry
Wellness and Fitness Services
Sub-industry
Digital health / allergy telehealth / sublingual immunotherapy
Offices
0 jobs at Wyndly
Check back later for new openings
Business model
Stage
Seed
Total raised
$2M
Latest round
Seed · Feb 2023
Latest amount
$2M
Feb 2023 · Y Combinator, Goodwater Capital, Civilization Ventures, Sweater Ventures, Kevin Mahaffey
Feb 2021 · Y Combinator
Leadership
Founder, Chief Executive Officer
Founder, Chief Medical Officer
Kent Northcote, MD
Physician
John Moustoukas, MD
Physician
Bhavesh Patel, MD
Physician
Nick Dahl, DO
Physician
Zara Patel, MD
Medical Advisor
Brian D’Anza, MD
Medical Advisor
Investors
Company messaging emphasizes doctor-led, patient-centered care, accessibility, personalization, and a culture built around compassion, focus, courage, and progress.
Benefits
Pricing
Direct-pay subscription with monthly treatment pricing, annual or quarterly billing options, and separate at-home test/consult pricing; treatment is HSA/FSA eligible and not primarily insurance-billed.
Differentiators
Technology
Customers
Competitors
Estimated revenue
USD 1M-10M
Estimated monthly visits
398.6K
Traffic estimate as of Jun 2026
Inc. · Aug 2025
Inc. profiles how Aakash and Manan Shah used Reddit and YouTube to grow Wyndly into a multimillion-dollar business, saying the company doubled sales in 2024 and surpassed $1M in its first year.
Founders Table · Sep 2024
Founder interview on the origin story, direct-to-consumer allergy care model, and Wyndly's growth strategy.
Tech Funding News · Feb 2023
Coverage of Wyndly's $2M round, the investors involved, and the company's allergy-drop telehealth model.
TechCrunch · Feb 2021
Early launch coverage explaining Wyndly's telemedicine-based allergy-drop offering, initial expansion states, and product pricing.